


## ORIGINAL ARTICLE

# Multicentre Delphi study of physicians resulted in quality indicators for young infants with fever without source in emergency departments

Roberto Velasco<sup>1</sup>  | Ainara Lejarzegi<sup>2</sup> | David Andina<sup>3</sup> | Borja Gomez<sup>2</sup> | Estíbaliz Izarzugaza<sup>4</sup> | Santiago Mintegi<sup>2</sup> | on behalf of the Spanish Pediatric Emergency Research Network Febrile Infant Study Group

<sup>1</sup>Paediatric Emergency Department, Hospital Universitario Rio Hortega, Valladolid, Spain

<sup>2</sup>Paediatric Emergency Department, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country (UPV/EHU), Bilbao, Spain

<sup>3</sup>Paediatric Emergency Department, Hospital Universitario Niño Jesús, Madrid, Spain

<sup>4</sup>Subdirector of Innovation and Quality, Hospital Universitario Cruces, University of the Basque Country (UPV/EHU), Bilbao, Spain

## Correspondence

Roberto Velasco, Paediatric Emergency Department, Hospital Universitario Rio Hortega, C/ Pisuerga, 7-3° B, 47140 Laguna de Duero, Valladolid, Spain.  
Email: [robertovelascozuniga@gmail.com](mailto:robertovelascozuniga@gmail.com)

## Abstract

**Aim:** Managing febrile infants has evolved without a generally accepted standard of care. We aimed to design quality indicators for managing infants  $\leq 90$  days old presenting to emergency departments (EDs) with fever without source.

**Methods:** This multicentre Delphi study was carried out by the Febrile Infant Study Group of the Spanish Paediatric Emergency Research Network, from March 2021 to November 2021, and included paediatric emergency physicians from 24 Spanish EDs. A list of care standards was produced, following an extensive literature review and the involvement of all parties. Indicators were essential if they were voted by four panelists and also received a score of  $\geq 4$  from at least 95% of the 24 investigators.

**Results:** We established 20 indicators, including one related to having a protocol, two to triage, nine to diagnostic processes, six to treatment and two to disposition. The following indicators were considered essential: having an ED management protocol, performing urinalysis on every infant, obtaining a blood culture from every infant and administering antibiotics in the ED to any febrile infant who did not appear well.

**Conclusion:** The Delphi method resulted in a comprehensive list of quality indicators for managing febrile young infants in Spanish EDs.

## KEYWORDS

bacterial infection, emergency, fever, infant, quality

## 1 | INTRODUCTION

A considerable proportion of febrile infants under 3 months of age who present to an emergency department (ED) have a bacterial infection.<sup>1,2</sup> These include invasive bacterial infections such as meningitis, bacteraemia and urinary tract infections. Invasive bacterial

infections have a prevalence of between 2% and 3% in this age group, although this rate is even higher in the first weeks of life. The traditional approach taken with these patients consisted of extensive evaluations, hospitalisation and antimicrobial treatment. However, the way that febrile infants under the age of 3 months are managed has changed considerably over the last two decades.

**Abbreviations:** ED, emergency department; IQR, interquartile range.

© 2023 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd

Nowadays, not all patients require admission and antibiotic treatment and those who have a very low risk for invasive bacterial infections can be identified and receive outpatient management.

The current management of young febrile infants varies widely, particularly in patients between 29 and 90 days of age.<sup>3</sup> These variations provide an opportunity to modify diagnostic and management strategies based on current epidemiologic research and safely decrease invasive testing and hospitalisation.<sup>4</sup>

Variations are an inherent part of clinical practice.<sup>5</sup> Some degree of variation, including that resulting from patient or family preferences, is considered appropriate. In contrast, inappropriate variations can have multiple causes and are not a by-product of patient and family centred care.<sup>6</sup> The aim of quality improvement initiatives is to learn from, and reduce, inappropriate variations.

Nearly all of the current protocols agree on certain aspects of managing febrile young infants, which are derived from evidence-based medicine. These include the need for complementary tests and admitting younger patients. However, even the most recent clinical tools show some discrepancies, as the 2021 guideline of the American Academy of Paediatrics has pointed out.<sup>7</sup> These differences can be detrimental to the quality of care delivery.<sup>8</sup> Research has highlighted the importance of identifying impediments in translating evidence-based recommendations into practice.<sup>9</sup> The development of quality indicators for managing young febrile infants in the ED could help to improve this situation.

The aim of this Spanish study was to design a series of quality indicators for managing infants  $\leq 90$  days old with fever without a source who presented to EDs.

## 2 | METHODS

We conducted a multicentre study of paediatric emergency physicians from 24 Spanish EDs from March 2021 to November 2021. The study was endorsed by the Spanish Paediatric Emergency Research Network, which is part of the Spanish Paediatric Emergency Society. By the time the study was carried out, RISEuP-SPERG comprised 127 investigators from 54 emergency departments. The Network aims to foster high-quality multi-institutional research on the prevention and treatment of diseases and acute injuries in children and adolescents.<sup>10</sup> It is also one of the multicentre research networks affiliated with Paediatric Emergency Research Networks.<sup>11</sup>

First, we formed a main working group comprising five panelists with expertise in research on febrile infants.<sup>12-15</sup> They conducted a literature search and a reading of the most relevant papers published since 2010 on febrile infants,<sup>2,7,16-23</sup> with special interest in the practice guidelines of the American Academy of Pediatrics.<sup>7</sup> Then, after this literature review, the group of panelists held two online meetings to draft an initial list of care standards for managing young infants, focusing on patients with fever without source. The list included standards that applied to the entire population of infants between 0 and 90 days of age with fever without source. Other

### Key notes

- This Delphi multicentre study aimed to design quality indicators for managing infants  $\leq 90$  days old presenting to emergency departments (EDs) with fever without source.
- It was carried out by the Febrile Infant Study Group of the Spanish Paediatric Emergency Research Network Febrile Infant Study Group, which included paediatric emergency physicians from 24 Spanish EDs.
- We established 20 indicators that covered such areas as having a protocol, triage, diagnostic processes, treatment and admissions.

standards only applied to certain age groups:  $\leq 21$ , 22–28, 29–60, and 61–90 days. Standards that were accepted unanimously by all the panelists were included in the list.

The Delphi method was used during the second phase. Prior to the start of the second phase, an invitation to participate in the study was sent to all members of the network, to which researchers from 27 hospitals responded. In those hospitals, where more than one investigator responded, they were asked to choose a champion, preferably the person with the most experience in febrile infants. The investigator from each 27 participating hospitals received access to an online questionnaire containing the list of care standards. The majority responded and 24 (89.9%) were included in the study. They were asked to evaluate the clinical relevance of each item using a 7-point Likert scale. Non-responders were sent email reminders 2, 4 and 8 weeks after the initial request.

After all responses were received, items scoring  $\geq 4$  by at least 70% of the site investigators were included in the final list; and items given a score of  $\geq 4$  by less than 50% were eliminated. Finally, we computed the median score and interquartile range (IQR) and mean score along with 95% confidence intervals for all importance ratings. In Delphi studies, the IQR serves as an indicator of interrater consensus. An IQR  $\leq 1$  is considered a strong consensus between raters, while an IQR  $\leq 2$  is considered a consensus for items rated on a 7-point scale.<sup>24</sup> The latter cut-off is considered acceptable for studies where outcomes do not represent an immediate threat to life.<sup>25</sup> As in other Delphi studies, we established cut-offs for the IQR ( $< 2$ ) and median importance score ( $\geq 6$ ) to identify indicators rated as highly important by consensus.<sup>24,25</sup>

In the final phase, the five panelists, in collaboration with a quality expert from one of the participating hospitals (EI) designed a quality indicator for each standard in the final list. For standards that were common to more than one age group, the working group tried to merge them into a single indicator. The indicators were designed to cover the six domains of Health Care Quality: Safe, Effective, Patient-centred, Timely, Efficient and Equitable.<sup>26</sup> Finally, each panelist chose, among those standards that received a score  $\geq 4$  in the Delphi by at least 95% of the participants, the eight indicators that

TABLE 1 List of standards of care for young febrile infants included in the Delphi questionnaire (n = 24 respondents).

| Age group (days old)  | Standard   | Mean score (95% CI)  | Median score (IQR) | Respondents with score $\geq 4$ |      |
|---|--|--|--------------------|---------------------------------|------|
| 0-90  | G1—The emergency department must have a management protocol for febrile infants up to 60/90 days old   | 6.73 (6.44-7)  | 7 (7-7)            | 100%                            |      |
|   | G2—The appearance of every infant must be registered   | 6.85 (6.70-6.99)   | 7 (7-7)            | 100%                            |      |
|   | G3—Rectal temperature must be registered in every infant   | 5.73 (5.19-6.27)   | 6 (5-7)            | 88.5%                           |      |
|   | G4—Urinalysis must be performed in every febrile infant  | 6.65 (6.23-7)  | 7 (7-7)            | 96.2%                           |      |
|   | G5—Antibiotic therapy must be given if the urinalysis is positive for leukocytes and/or nitrites   | 6.04 (5.47-6.60)   | 6.5 (6-7)          | 96.2%                           |      |
|   | G6—Antibiotic therapy must be given if any biomarker is found to be abnormal   | 5.62 (5.08-6.15)   | 6 (5-7)            | 92.3%                           |      |
|   | G7—Lumbar puncture (LP) must be performed in every patient not appearing well or those with clinical suspicion of sepsis/meningitis/encephalitis                                       | 6.69 (6.44-6.94)   | 7 (7-7)            | 100%                            |      |
|   | G8—Parenteral antibiotic therapy must be given to every patient not appearing well or those with clinical suspicion of sepsis/meningitis   | 6.92 (6.81-7)  | 7 (7-7)            | 100%                            |      |
| 0-21  | G9—Blood enterovirus polymerase chain reaction testing must be performed in epidemic season  | 5.35 (4.71-5.98)   | 5 (4-7)            | 88.5%                           |      |
|   | G10—A rapid test for influenza should be performed in epidemic season  | 5.73 (5.21-6.25)   | 6 (5-7)            | 96.2%                           |      |
|   | A1—A urine sample must be obtained by catheterisation or suprapubic aspiration of the bladder in every febrile infant $\leq 21$ days old   | 6.73 (6.52-6.95)   | 7 (7-7)            | 100%                            |      |
|   | A2—A blood biomarker value must be obtained for every febrile infant $\leq 21$ days old  | 6.54 (6.12-6.95)   | 7 (7-7)            | 96.2%                           |      |
|   | A3—Blood culture must be obtained for every febrile infant $\leq 21$ days old  | 6.88 (6.75-7)  | 7 (7-7)            | 100%                            |      |
|   | A4—LP must be performed in every febrile infant $\leq 21$ days old   | 6.27 (5.88-6.66)   | 7 (6-7)            | 100%                            |      |
|   | A5—Parenteral antibiotic therapy must be given to every febrile infant $\leq 21$ days old  | 6.12 (5.60-6.63)   | 7 (5-7)            | 92.3%                           |      |
|   | A6—Every febrile infant $\leq 21$ days old must be admitted  | 6.69 (6.40-6.99)   | 7 (7-7)            | 100%                            |      |
|   | 22-28  | B1—A urine sample must be obtained by catheterisation or suprapubic aspiration of the bladder in every febrile infant 22-28 days old with a positive leukocyte esterase (LE) or nitrite test | 6.85 (6.70-6.99)   | 7 (7-7)                         | 100% |
|   |  | B2—A blood biomarker value must be obtained in every febrile infant 22-28 days old   | 6.73 (6.52-6.95)   | 7 (7-7)                         | 100% |
| B3—Blood culture must be obtained in every febrile infant 22-28 days old  |  | 6.85 (6.70-6.99)   | 7 (7-7)            | 100%                            |      |
| B4—LP must be performed in every febrile infant 22-28 days old with altered biomarkers  |  | 5.85 (5.39-6.30)   | 6 (5-7)            | 100%                            |      |
| B5—Parenteral antibiotic therapy must be administered to every febrile infant 22-28 days old with pleocytosis   |  | 6.50 (6.15-6.85)   | 7 (6-7)            | 100%                            |      |
| B6—Every febrile infant 22-28 days old with pleocytosis must be admitted  |  | 6.65 (6.40-6.91)   | 7 (6-7)            | 100%                            |      |
| B7—Antibiotic therapy must not be given in well-appearing febrile infants 22-28 days old with negative urine dipstick, normal biomarkers, and without pleocytosis (or LP not performed) |  | 6.46 (6.20-6.72)   | 7 (6-7)            | 100%                            |      |
| 29-60   | C1—A urine sample must be obtained by catheterisation or suprapubic aspiration (SPA) of the bladder in every febrile infant 29-60 days old with a positive LE or nitrite test          | 6.88 (6.75-7)  | 7 (7-7)            | 100%                            |      |
|   | C2—A blood biomarker value must be obtained in every febrile infant 29-60 days old   | 6.50 (6.15-6.85)   | 7 (6-7)            | 100%                            |      |
|   | C3—A blood culture must be obtained in every febrile infant 29-60 days old   | 6.65 (6.40-6.91)   | 7 (6-7)            | 100%                            |      |
|   | C4—Parenteral antibiotic therapy must be given to every febrile infant 29-60 days old with pleocytosis   | 6.46 (6.13-6.79)   | 7 (6-7)            | 100%                            |      |
|   | C5—Every febrile infant 29-60 days old with pleocytosis must be admitted   | 6.27 (5.74-6.80)   | 7 (6-7)            | 96.2%                           |      |
|   | C6—Antibiotic therapy must not be given in well-appearing febrile infants 29-60 days old with negative urine dipstick, normal biomarkers and without pleocytosis (or LP not performed) | 6.38 (5.94-6.83)   | 7 (6-7)            | 96.2%                           |      |

TABLE 1 (Continued)

| Age group (days old) | Standard   | Mean score (95% CI) | Median score (IQR) | Respondents with score $\geq 4$ |
|----------------------|--|---------------------|--------------------|---------------------------------|
| 61–90                | D1—A urine sample must be obtained by catheterisation or SPA of the bladder in every febrile infant 61–90 days old with a positive LE or nitrite test  | 6.85 (6.70–6.99)    | 7 (7–7)            | 100%                            |
|                      | D2—A blood biomarker value must be obtained in every febrile infant 61–90 days old   | 6.08 (5.67–6.49)    | 6 (5–7)            | 100%                            |
|                      | D3—A blood culture must be obtained in every febrile infant 61–90 days old   | 6.23 (5.83–6.63)    | 6.5 (6–7)          | 96.2%                           |
|                      | D4—Parenteral antibiotic therapy must be given to every febrile infant 61–90 days old with pleocytosis   | 5.92 (5.32–6.53)    | 7 (5–7)            | 92.3%                           |
|                      | D5—Every febrile infant 61–90 days old with pleocytosis must be admitted   | 6.11 (5.48–6.75)    | 7 (5–7)            | 92.3%                           |
|                      | D6—Antibiotic therapy must not be administered to well-appearing febrile infants 61–90 days old with negative urine dipstick, normal biomarkers, and without pleocytosis (or LP not performed) | 6.58 (6.16–6.99)    | 7 (6–7)            | 96.2%                           |

they considered most relevant. Those selected by at least four panelist were considered essential.

Although the study did not include patient participation, we obtained the approval of the Ethics Committee of the Basque Country. Completion of the questionnaire was considered an indication of consent to participate.

### 3 | RESULTS

After the first phase, we drafted a list of 35 standards of care: 10 were related to the entire population of febrile infants, six to those  $\leq 21$  days of age, seven to patients 22–28 days old, six to those

TABLE 2 Final list of care-quality indicators for young febrile infants after the last phase of the study.

#### Protocol

- **Existence of a management protocol for febrile infants  $\leq 90$  days old**

#### Triage

- Febrile infants  $\leq 90$  days old with a record of their appearance on arrival at the emergency department
- Febrile infants  $\leq 90$  days old with rectal temperature measurement

#### Diagnosis

- **Febrile infants  $\leq 90$  days old screened for leukocyturia/nitrituria**
- Febrile infants  $\leq 90$  days old with a urine culture
- Febrile infants 22–90 days old with blood biomarkers levels obtained
- **Febrile infants  $\leq 90$  days old with blood culture**
- Febrile infants  $\leq 90$  days old not appearing well with lumbar puncture
- Febrile infants  $\leq 21$  days old with lumbar puncture
- Febrile infants 22–28 days with abnormal biomarkers and lumbar puncture
- Febrile infants 22–90 days old with a blood polymerase chain reaction for enterovirus performed during the epidemic season
- Febrile infants  $\leq 90$  days old with a rapid diagnostic test for influenza performed during the epidemic season

#### Treatment

- **Febrile infants  $\leq 90$  days old not appearing well with antibiotic therapy**
- Febrile infants  $\leq 90$  days old with a suspected urinary tract infection and antibiotic therapy
- Febrile infants  $\leq 21$  days old administered antibiotic therapy
- Well-appearing febrile infants 22–90 days old with normal urine dipstick and altered blood biomarkers with antibiotic therapy administered
- Well-appearing febrile infants 22–90 days old with normal urine dipstick and pleocytosis with antibiotic therapy administered
- Febrile infants  $\leq 90$  days old with low-risk criteria and no antibiotic therapy

#### Disposition

- Febrile infants  $\leq 21$  days old admitted to ward/intensive care unit
- Febrile infants 22–90 days old with pleocytosis admitted to ward/intensive care unit

Note: Indicators considered essential appear in bold.

29–60 days of age, and six to febrile infants between the ages of 61 and 90 days. We forwarded a questionnaire compiled from the entire list to one investigator from each of the 27 participating hospitals and received 24 (88.9%) responses (Table 1). Among the 24 hospitals from which responses were received, there was at least one from 11 of the 17 Spanish regions. All were secondary or tertiary, with a range of volume of patients from 4300 to 65000 patients/year. All the proposed standards obtained a score of  $\geq 4$  from more than 70.0% of the participants. All but one item were deemed highly important by consensus. As Table 1 shows, pandemic-season blood enterovirus polymerase chain reaction testing was the only standard given a median score of 5 (IQR 3).

We merged standards that were common to more than one age group, establishing a final list of 20 standards. Following this, a quality indicator was created for each standard. Table 2 contains the entire list of indicators. Of these, one was related to having a protocol or an adapted guide, two to triage, nine to the diagnostic process, six to treatment and two to disposition, thus covering the six domains of healthcare quality. Table 3 shows the four essential indicators: having an ED management protocol, performing urine

analysis in every infant, obtaining a blood culture in every infant and administering antibiotics in the ED to any febrile infant who appeared ill.

## 4 | DISCUSSION

This three-phase consensus study of 30 experts (five panelists, one investigator of each participant hospital and one quality expert) resulted in a 20-item set of quality indicators established with a high level of expert consensus. These indicators represent five clinical domains for infants  $\leq 90$  days old with fever without source, and four of the standards were deemed essential.

Previous research has found variation in the management of the febrile infant.<sup>4,8</sup> One reason for this lack of uniformity is the absence of validated standards of care. The clinical guideline published in 2021 by the American Academy of Pediatrics aimed to organise the recommendations of the institution into key action statements, which are a good proxy for standards of care.<sup>7</sup> Here, we aimed to take this idea one step further by developing a series of

TABLE 3 List of the essential care-quality indicators for young febrile infants.

| Indicator            | Existence of a management protocol for febrile infants $\leq 90$ days old  | Febrile infants $\leq 90$ days old with a performed screening of leukocyturia/nitrituria   |
|----------------------|--|--|
| Dimension            | Effectiveness, safety, patient-centredness, timeliness, efficiency, equity   | Effectiveness, safety  |
| Justification        | Good clinical practice is facilitated by standardised processes in accordance with existing scientific evidence through regularly updated protocols. Protocols must adapt management guidelines to the diagnostic and therapeutic possibilities of the local environment to homogenise clinical care and act as a tool that facilitates and expedites decision-making. | Urinary tract infection (UTI) is the most common serious bacterial infection in febrile young infants. For this reason, UTI should be considered in all these patients. Urine dipstick testing for leukocyturia/nitrituria has adequate sensitivity for the diagnosis of UTI |
| Formula              | Existence of a clinical protocol in the ED for the management of febrile infants $\leq 90$ days old based on current evidence and updated over the last 5 years<br>YES/NO  | $\frac{\text{Febrile infants } \leq 90 \text{ days old screened for leukocyturia / nitrituria in the ED}}{\text{Febrile infants } \leq 90 \text{ days old presenting to the ED}} \times 100$   |
| Explanation of terms | Minimum protocol contents: diagnostic and therapeutic methods and a decision-making aid. The existence of a protocol making reference to febrile infants $\leq 60$ days old will also be considered valid  | Screening for leukocyturia/nitrituria either by urine dipstick (at the bedside or in the laboratory) or microscopic analysis is considered valid   |
| Population           | List of ED protocols   | All febrile infants $\leq 90$ days old presenting to the ED during the study period  |
| Type                 | Structure  | Process  |
| Data source          | ED protocols   | Review of discharge forms in the electronic medical record or, failing that, on paper, corresponding to febrile infants $\leq 90$ days old presenting to the ED during the period studied  |
| Standard             | 100%   | Higher than 95%  |
| Remarks              | Each ED must have its own protocols or adapt protocols designed by other EDs or scientific societies. Protocols must be based on current evidence and be updated every five years at the latest  |  |

ED care-quality indicators, possibly benchmarking these indicators against others like it.

Variability is inherent to clinical practice and is not necessarily harmful. However, there exists a so-called unjustified variability, when medical care disregards patient preferences or current scientific knowledge of the underlying disease.<sup>27</sup> Unjustified variability is always multicausal and depends on factors such as the increasing complexity of health care, lack of valid clinical knowledge, or overconfidence in subjective judgements.<sup>6</sup>

One strength of our quality indicators was that they were designed by expert panelists with deep knowledge of research on the febrile infant. Furthermore, the indicators were externally validated through a Delphi process. The Delphi method was specifically designed to achieve group consensus and has been successfully applied to clinical best practices.<sup>28</sup> The method is based on iterative, controlled interaction between diverse respondents across geographic locations. Unlike other exploratory qualitative methods such as interviews and focus groups, respondents are blinded to each other, and no individual can dominate or influence group thinking. Furthermore, panelists are privy to the

responses of their fellow experts and can reconsider their own position in the light of group patterns. Thus, the Delphi process facilitates consensus through anonymous communication without confrontation.<sup>28</sup>

Another strength of our study was that our list concerns infants from birth to 90 days of age. Although patients  $\leq 7$  days old were excluded from the current American Academy of Pediatrics guideline, we believed that there was ample evidence in favour of managing these patients in the same way as patients between 8 and 21 days of age.<sup>15,16,20</sup> Although some authors recommend a different approach for febrile infants  $> 60$  days old, given the prevalence of urinary tract infection and bacteraemia among these patients,<sup>19</sup> we considered it appropriate to include this group.

One of the most difficult steps in the process involved selecting which indicators should be considered essential. By way of example, 15 of the 20 indicators were believed to be essential by at least one panelist. Finally, a majority of panelists believed it essential for every febrile infant to be managed in accordance with a current evidence-based protocol; that the two most frequent bacterial infections, urinary tract infection and bacteraemia, be ruled out in every infant;

| Febrile infants $\leq 90$ days old with blood culture   | Ill-appearing febrile infants $\leq 90$ days old with antibiotic administered  |
|---|--|
| Effectiveness, safety   | Effectiveness, safety  |
| The prevalence of bacteraemia in febrile infants $\leq 90$ days old is higher than 2%. Many of these patients are well appearing and have a normal physical examination on arrival to the emergency department (ED). For this reason, all patients should have a blood culture. | The main risk factor associated with the diagnosis of invasive bacterial infection in a febrile infant $\leq 90$ days old is appearing unwell. For this reason, empirical antibiotic therapy should be administered to all such febrile infants in the emergency department (ED)   |
| $\frac{\text{Febrile infants } \leq 90 \text{ days old with a blood culture obtained in the ED}}{\text{Febrile infants } \leq 90 \text{ days old presenting to the ED}} \times 100$   | $\frac{\text{Febrile infants } \leq 90 \text{ days old with an unwell appearance were administered antibiotics in the ED}}{\text{Febrile infants } \leq 90 \text{ days old presenting to the ED with an unwell appearance}} \times 100$  |
|   | A patient is considered to appear unwell when expressions such as "poor general condition", "unresponsive", "toxic appearance", or similar appear in the medical record. If the Paediatric Assessment Triangle is used in the ED, patients with abnormal findings on any side of the triangle are considered to appear unwell. |
| All febrile infants $\leq 90$ days old presenting to the ED during the study period   | All febrile infants $\leq 90$ days old present to the ED during the period studied   |
| Process   | Process  |
| Review of discharge forms in the electronic medical record or, failing that, on paper, corresponding to febrile infants $\leq 90$ days old presenting to the ED during the study period   | Review of discharge forms in the electronic medical record or, failing that, on paper, corresponding to febrile infants $\leq 90$ days old presenting to the ED during the study period  |
| Higher than 95%   | Higher than 95%  |



and that all infants who appeared will be given early parenteral antibiotics, as they are at high risk for invasive bacterial infection.

Our study had certain limitations. As explained above, it must be noted that the standards of care designed in this study are focused on the management of young infants with fever without a source, in contrast to different guidelines or recommendations that include all young febrile infants. Thus, this should be considered for external validation, and, if so, should be very cautiously applied to young febrile infants with fever with a source. Aside from this, a significant limitation was the number of participants in the Delphi process. To avoid the overrepresentation of larger institutions in our network, only one investigator per hospital completed the questionnaire, preferably the researcher with the most expertise. As a result, the number of participants may appear small. However, the study included half of the member hospitals of the Spanish Pediatric Emergency Research Network, therefore, lending sufficient validity to our findings. Second, the quality indicators were developed in a single country, which could limit their external validity. In any case, the Spanish public healthcare system is controlled on the regional level, that is by 17 regional ministries of health. We obtained responses from EDs in 11 of the 17 Spanish regions; these included EDs that are secondary and tertiary, paediatric and mixed-age, rural and urban, and with both small and large patient volumes. We therefore believe that this broad inclusion of participating centres partially mitigates the impact of this limitation. Furthermore, the indicators are being validated in a subsequent study in the same participating hospitals, and it would be ideal to culminate the process with an international multicentre validation. An additional limitation was the fact that the consensus-based indicators have not been validated in real clinical practice. However, this was the first phase of a larger study examining the application of the indicators. Fourth, these indicators focused on bacterial infections, which eliminated other possible aetiologies, such as viruses. Since some of these viruses can develop into sepsis-like illnesses, this aetiology must also be taken into account. However, as most severe illnesses are bacterial, the list of indicators was adequate for the vast majority of febrile infants. Lastly, some of the indicators included blood biomarker determinations, although biomarkers such as procalcitonin and C-reactive protein are scarcely used in some countries. The working group set out to use the most robust, current evidence to create the standards, and therefore the indicators must mention those biomarkers with the best performance. However, we aimed to provide a valid alternative to all indicators for EDs with more limited resources. For example, in hospitals without access to procalcitonin, C-reactive protein, and absolute neutrophil count, we recommend procalcitonin in conjunction with one of the other two.

## 5 | CONCLUSION

Using a standardised method, we created a comprehensive list of quality indicators for ED management of febrile young infants. Our

findings may form the basis for implementation of corrective measures and continuous quality improvement.

## ACKNOWLEDGEMENTS

We are grateful to the members of the Febrile Infant Study Group of the Spanish Pediatric Emergency Research Network: Amaia Cámara (San Sebastián), Ana Muñoz (Madrid), Andres González (Bilbao), Anna Pizà (Terrasa), Antonio de Francisco (Badalona), Carlos García-Vao (Aranjuez), Clara Ferrero (Madrid), Clàudia Coderch (Terrasa), Daniel De la Rosa (Gran Canaria), Jone Amasorrain (Mendaro), Laura Díaz (Barcelona), Leticia González (Segovia), Maria José Carbonero (Seville), Mariano Plana (Barbastro), Nuria Clerigue (Pamplona), Núria Gilabert (Mallorca), Ramón Fernández (Gijón), Sandra Moya (Sabadell), Sara Pons (Valencia) and Virginia Gómez (Zaragoza).

## FUNDING INFORMATION

This study did not receive any specific funding.

## CONFLICT OF INTEREST STATEMENT

The authors have no conflicts of interest to declare.

## ORCID

Roberto Velasco  <https://orcid.org/0000-0003-0073-2650>

## REFERENCES

- Bressan S, Andreola B, Cattelan F, Zangardi T, Perilongo G, da Dalt L. Predicting severe bacterial infections in well-appearing febrile neonates: laboratory markers accuracy and duration of fever. *Pediatr Infect Dis J*. 2010;29(3):227-232.
- Gomez B, Bressan S, Mintegi S, et al. Diagnostic value of procalcitonin in well-appearing young febrile infants. *Pediatrics*. 2012;130(5):815-822.
- Goldman RD, Scolnik D, Chauvin-Kimoff L, et al. Practice variations in the treatment of febrile infants among pediatric emergency physicians. *Pediatrics*. 2009;124(2):439-445.
- Rogers AJ, Kuppermann N, Anders J, et al. Practice variation in the evaluation and disposition of febrile infants ≤60 days of age. *J Emerg Med*. 2019;56(6):583-591.
- Glover JA. The paediatric approach to tonsillectomy. *Arch Dis Child*. 1948;23(113):1-6.
- James B. Quality improvement opportunities in health care-making it easy to do it right. *J Manag Care Pharm*. 2002;8(5):394-399.
- Pantell RH, Roberts KB, Adams WG, et al. Evaluation and management of well-appearing febrile infants 8–60 days old. *Pediatrics*. 2021;148(2):e2021052228.
- Aronson PL, Thurm C, Alpern ER, et al. Variation in care of the febrile young infant. *Pediatrics*. 2014;134(4):667-677.
- Meehan WP, Fleegler E, Bachur RG. Adherence to guidelines for managing the well-appearing febrile infant: assessment using a case-based, interactive survey. *Pediatr Emerg Care*. 2010;26(12):875-880.
- Mintegi S, Gómez B, de la Torre M. Progreso de la Red de Investigación de la Sociedad Española de Urgencias de Pediatría - Spanish Pediatric Emergency Research Group (RISEUP-SPERG). *Emergencias*. 2015;27:204-210.
- Klassen T, Dalziel SR, Babl FE, et al. The pediatric emergency research network: a decade of global research cooperation in pediatric emergency care. *Pediatr Emerg Care*. 2021;37(7):389-396.

12. de la Torre M, de Lucas N, Velasco R, et al. Aetiology and outcomes of potentially serious infections in febrile infants less than 3 months old. *An Pediatr*. 2017;87(1):42-49.
13. Poletto E, Zanetto L, Velasco R, da Dalt L, Bressan S. Bacterial meningitis in febrile young infants acutely assessed for presumed urinary tract infection: a systematic review. *Eur J Pediatr*. 2019;178(10):1577-1587.
14. Velasco R, Lejarzegi A, Gomez B, et al. Febrile young infants with abnormal urine dipstick at low risk of invasive bacterial infection. *Arch Dis Child*. 2020;106:758.
15. Gomez B, Mintegi S, Bressan S, et al. Validation of the "step-by-step" approach in the management of young febrile infants. *Pediatrics*. 2016;138(2):e20154381.
16. Mintegi S, Bressan S, Gomez B, et al. Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection. *Emerg Med J*. 2014;31:e19-e24.
17. Tzimenatos L, Mahajan P, Dayan PS, et al. Accuracy of the urinalysis for urinary tract infections in febrile infants 60 days and younger. *Pediatrics*. 2018;141(2):e20173068.
18. Pintos C, Mintegi S, Benito J, Aranzamendi M, Bonilla L, Gomez B. Blood enterovirus polymerase chain reaction testing in young febrile infants. *Arch Dis Child*. 2021;1-5:1179-1183.
19. Bonilla L, Gomez B, Pintos C, Benito J, Mintegi S. Prevalence of bacterial infection in febrile infant 61-90 days old compared with younger infants. *Pediatr Infect Dis J*. 2019;38:1163-1167.
20. Gomez B, Diaz H, Carro A, Benito J, Mintegi S. Performance of blood biomarkers to rule out invasive bacterial infection in febrile infants under 21 days old. *Arch Dis Child*. 2018;104(6):547-551.
21. Velasco R, Benito H, Mozun R, et al. Using a urine dipstick to identify a positive urine culture in young febrile infants is as effective as in older patients. *Acta Paediatr*. 2015;104(1):39-44.
22. Nigrovic LE, Malley R, Agrawal D, Kuppermann N. Low risk of bacterial meningitis in children with a positive enteroviral polymerase chain reaction test result. *Clin Infect Dis*. 2010;51(10):1221-1222.
23. Nigrovic LE, Mahajan PV, Blumberg SM, et al. The Yale observation scale score and the risk of serious bacterial infections in febrile infants. *Pediatrics*. 2017;140(1):e20170695.
24. Huijben JA, Wiegers EJA, De Keizer NF, et al. Development of a quality indicator set to measure and improve quality of ICU care for patients with traumatic brain injury. *Crit Care*. 2019;23:1-13.
25. Hung Y, Hieke S, Grunert KG, Verbeke W. Setting policy priorities for front-of-pack health claims and symbols in the European union: expert consensus built by using a delphi method. *Nutrients*. 2019;11(2):403.
26. Institute of Medicine (U.S.). Committee on Quality of Health Care in America. *Crossing the Quality Chasm*. National Academies Press; 2001.
27. Wennberg J, Gittelsohn A. Small area variations in health care delivery. *Science*. 1973;182(4117):1102-1108.
28. Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. *J Clin Epidemiol*. 2003;56(12):1150-1156.

**How to cite this article:** Velasco R, Lejarzegi A, Andina D, Gomez B, Izarzugaza E, Mintegi S, et al. Multicentre Delphi study of physicians resulted in quality indicators for young infants with fever without source in emergency departments. *Acta Paediatr*. 2023;112:1962-1969. <https://doi.org/10.1111/apa.16851>